Objective. To assess the outcome of adult patients with JIA who received etanercept (ETA) during childhood.
Introduction
JIA is a clinically heterogeneous group of disorders characterized by persistent joint inflammation. JIA may result in life-long disability and a reduced quality of life, particularly in patients who develop polyarthritis and who do not respond satisfactorily to treatment [13] . The advent of novel and potent biologic medications has been of great importance in the management of severe polyarticular JIA. Current treatment strategies allow for a normalization of inflammation in the majority of these patients in the first treatment years [4, 5] . However, the disease often relapses after discontinuing drug therapy [6, 7] . Therefore, most JIA patients are typically treated with one or more medications and increasingly more often with biologic drugs over the long term. However, whether exposure to these medications over an extended period of time during childhood can prevent damage and disability in adulthood, or results in any risk of morbidity is still unknown.
In 2001, just after the licensing of etanercept (ETA) as the first biologic drug for JIA in Germany, the national register BiKer [Biologika in der Kinderrheumatologie (Biologics in Paediatric Rheumatology)], was set up to monitor children treated with ETA [8] . Patients who started with ETA were eligible for inclusion in BiKer. In 2005 the register was extended to include a control group, which consists of biologic-naïve JIA patients who started with the conventional DMARD, MTX. In the year 2007, >1200 JIA patients were included in BiKer. However, the mean observation period per patient was <2 years. Accordingly, a further observation of the grown-up patients seemed indispensable in order to obtain reliable data on biologic drug long-term safety. Thus JuMBO (Juvenile arthritis MTX/Biologics long-term Observation) was launched as the BiKer follow-up register in 2007. This happened at a time when almost 400 patients were already lost to follow-up from BiKer for age-related reasons.
JuMBO aims at a follow-up of all JIA patients formerly included in BiKer into adulthood with age-specific instruments in order to gather information on the long-term effectiveness and safety of biologic drugs. Here, the methods and first results are presented. The data relate to the patients' current status, but not to the entire disease course after the start of biologic drug treatment.
Methods

Patients
Patients with definite JIA according to the ILAR criteria [9] , who were enrolled in BiKer and had reached 18 years of age and/or left paediatric rheumatology care are eligible for participation in JuMBO. Because JuMBO started 6 years after BiKer, patients already lost to follow-up had to be contacted in written form by the paediatric rheumatology unit under which they were formerly cared for at the last known address and asked to participate in JuMBO. Those who were still being cared for at a paediatric unit were asked about participation before being transferred to adult care. The patient's written consent was obtained according to the Declaration of Helsinki. After receiving the patients' consent, the German Rheumatism Research Centre (DRFZ) contacted the patients and sent them the first patient and physician questionnaire. The patients were requested to forward the physician questionnaire to their current treating physician and to complete the patient questionnaire at the time of their visit to the physician. After the first documentation in JuMBO, the patients have been contacted twice a year by the DRFZ and provided with follow-up questionnaires. If a patient does not regularly visit a rheumatologist or a treating physician is not willing to participate in JuMBO, only the patient-reported outcomes are considered. This patientoriented study monitoring was chosen with regard to the following facts: (i) adult patients with JIA do not always remain in rheumatology care; (ii) the further caring doctors are not always known at the time when the patients leave paediatric care; and (iii) young people relatively often change doctors, e.g. due to transient living situations and frequent relocation. JuMBO was established at the DRFZ, where the study centre for the biologic register for adults with RA [Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT)] is located [10] . Similar case report forms and a similar procedure as in RABBIT were used in JuMBO with which many German adult rheumatologists were already familiar. This procedure was chosen to use the existing infrastructure and experience and to facilitate participation by adult rheumatologists.
Patient recruitment is ongoing. In the following analyses, patients who were enrolled up to 31 December 2010 were included. All follow-up data available until this time point were used.
Procedures and assessments
JuMBO is a prospective observational cohort study. Patients are examined every 6 months. At each measurement time point a patient questionnaire and a short clinical record are employed.
In order to assess patients' disability and health-related quality of life (HRQoL), the HAQ and the Medical Outcomes Short Form-36 (SF-36) are applied as wellestablished measurement tools in adult rheumatology [11, 12] . The SF-36 survey yields an eight-scale profile of functional health and well-being (physical functioning, role physical, bodily pain, general health, vitality, role emotional, social functioning and mental health), as well as two comprehensive HRQoL indexes: the physical component summary (PCS) and the mental component summary (MCS) score. Both summary scores are obtained from normalized and z-transformed domain scores.
Patients also assess their pain, general health, fatigue and disease activity on an 11-point numeric rating scale (NRS) from 0 to 10 (10 being the worst status imaginable). A value of 0 is regarded as no pain, fatigue or disease activity, respectively. Additionally, basic sociodemographic data, hospitalizations, educational/vocational situation and important health problems from the patient's point of view are recorded.
The treating physician is asked to record the following: number of joints with swelling, tenderness or pain on motion, limited range of motion (72-joint count), the ESR, the CRP level, morning stiffness and conventional and/or biologic DMARD therapy, including details of starting and ending therapy, reasons for change of treatment and concomitant therapies with glucocorticoids or NSAIDs. Physicians assess the patient's disease activity on an NRS. The criteria by Wallace et al. [13] were applied to define inactive disease or remission. Minimal disease activity was defined according to the definition for polyarticular JIA by Magni-Manzoni et al. [14] . Additionally, physicians record known comorbid conditions at inclusion in JuMBO and any adverse or serious adverse events (AEs or SAEs) that occur thereafter. An AE is defined as any untoward medical occurrence that occurred during observation. An SAE is defined according to the International Conference on Harmonization guideline E2A [15] as any untoward medical occurrence that occurs during observation and results in death, a life-threatening illness, hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect or a medically significant event determined by the responsible local physician that in their opinion jeopardized the health of the patient and required intervention to prevent one of the other outcomes listed. AEs and SAEs are recorded half-yearly as part of the regular patient visit. Only at the first JuMBO visit, physicians report on SAEs that occurred during the preceding 12 months. Here, the 12-month period was chosen in order to bridge the transitional period between paediatric and adult health care (i.e. BiKer and JuMBO). For reasons of quality assurance, the physicians are provided with the definitions of AEs and SAEs, as well as with the suggestion to grade AEs as mild, moderate or severe, according to the proposal of the Outcome Measures in Rheumatology Clinical Trials conference [16] . In the event of lack of physician-reported safety data and a patient report on a relevant health problem, confirmation of this event is sought by any physician involved in the care of that patient. The Medical Dictionary for Regulatory Activities (MedDRA) has been used to classify AEs and SAEs. The study was approved by the ethics committee of the Charité Medical School, Berlin. 
Results
On 31 December 2010, 346 patients who ever received ETA were included and assessed at least once in JuMBO. At the last documentation in JuMBO, 78% of the patients were still on conventional or biologic DMARDs, 45% on ETA alone. This means, 6.5 years (median; IQR 4.28.4 years) after starting with ETA and inclusion in BiKer, 22% of the patients had stopped DMARD treatment and 33% had continued DMARD treatment without ETA. The drugs with which the patients were treated at last documentation are presented in Table 1 together with the patients' characteristics. In general, over the course of the disease, the patients had received 3.5 different conventional or biologic DMARDs (range 113) other than ETA. Among these were MTX, adalimumab, SSZ, AZA, LEF, infliximab, anti-malarials, CSA, anakinra, MMF, gold, CYC and chlorambucil in decreasing order.
The patients who were still on ETA at the last documentation had a median ETA treatment duration of 4.1 years [range 110, IQR 26 years (mean 4.6)]. The patients included in this analysis were not significantly different from those (n = 281) for whom no completed JuMBO questionnaire was available in December 2010 or who were lost to follow-up with regard to the following: JIA subtype, sex, disease activity and functional status (according to the Childhood Health Assessment Score) at last documentation in BiKer. Of those 281 patients, 90 already agreed to participate in JuMBO, whereas another 93 refused. Three subjects were deceased before they could be included in JuMBO. The remaining patients are still being sought.
One-fifth of the 346 patients had completed only one JuMBO assessment and 70% were examined three times. The median observation period in JuMBO was 1.5 years. The drop-out rate of patients after the first assessment in JuMBO was 3%. However, physician data were not available for 87 patients (25%) because the patients did not regularly visit a rheumatologist or the physician was not willing to participate.
Outcomes
At the last follow-up, physicians rated the disease as being inactive (NRS = 0) in 26% of the patients. Nineteen per cent of the patients had an inactive disease (or were in remission on medication) according to the Wallace criteria, while only 6% were in a state of clinical remission off medication. Another 38% fulfilled the criteria for being in a state of minimal disease activity according to the criteria by Magni-Manzoni.
According to the patients' self-ratings (NRS = 0), 24% of the patients had an inactive disease. About half of them (49%) reported no functional limitations (HAQ score = 0). The functional status of patients, referring to the different JIA subgroups, is shown in Fig. 1 . Fatigue was reported more frequently, namely by 76% of patients. One in four patients suffered from moderate to severe fatigue (NRS 54).
Twenty-five per cent of the patients had undergone at least one JIA-related joint operation, most frequently those with systemic arthritis. The patients with joint operations had a significantly longer mean disease duration than the patients without operations (14 vs 9 years). Although 38% of the patients with a disease duration >10 years had joint surgery, this applied to only 16% of the patients with a disease duration of 410 years. Operations comprised arthroscopies and synovectomies in 15%, endoprosthesis in 5.8% and arthrodesis in 2.9% of the cases.
By means of the SF-36, the patients judged their HRQoL to be lower than a reference group of the same age range from the general population [17] . However, this was only the case regarding physical functioning, bodily vitality, pain, general health and physical role (Fig. 2) . In comparison with a clinic-based cohort of adults with JIA treated in the pre-biologic era, the JuMBO patients reported a higher HRQoL [18] . The PCS scores of the JuMBO patients were 43.3 and 47.5 for women and men, and the MCS scores were 50.1 and 51.0, respectively (Table 2 ). Multivariate ANCOVA yielded that the functional capacity [F(324,3) = 80.6; P < 0.001] and perceived fatigue [F(324,3) = 13.5; P < 0.001] had an independent significant effect on patients' physical health, whereas www.rheumatology.oxfordjournals.org
TABLE 1
Characteristics of patients (n = 346) at last documentation Other JIA (n = 15)
All patients
Female, n (%)
12 (55) 7 (64) 39 (77) 73 (81) 36 (82) 36 (48) 23 (61) 8 (53) 234 ( 15 (1218) 12 (716) 16 (1218) 11 (816) 9 (612) 8 (611) 9 (612) 10 (712) 10 (715) Months since first assessment in JuMBO, median (IQR)
22 (1727) 13 (521) 13 (323) 16 (725) 15 (624) 22 (1529) 13 (423) 19 (1028) 18 (927) Disease activity rated by physician (NRS 010), median (IQR)
2 (13) 1 (02) 2 (03) 1 (03) 2 (13) 1 (02) 1 (02) 1 ( 2 (15) 3 (15) 3 (16) 2 (03) 3 (14) 2 (27) 2 (15) Current DMARD treatment, n (%) ETA 5 (23) 4 (36) 22 (43) 48 (53) 25 (57) 30 (40) 16 (42) 6 (40) 156 (45) MTX 9 (41) 3 (27) 16 (31) 31 (34) 20 (46) 18 (24) 18 (47) 5 (33) 120 ( 1 (9) 10 (20) 12 (13) 10 (23) 13 (17) 8 (21) 2 (13) 59 (17) LEF 2 (9) 1 (9) 7 (14) 11 (12) 7 (16) 2 (3) 1 (3) 1 (7) 32 ( 2 (4) 5 (6) 1 (2) 1 (1) 1 (3) 1 (7) 12 (4)
3 (6) 1 (1) 0 (0) 4 (5) 1 (3) 3 (20) 13 ( 2 (4) 3 (3) 1 (2) 1 (1) 2 (5) 1 (7) 12 ( fatigue was the only independent factor significantly influencing patients' psychosocial health [(F(324,3) = 15.0; P < 0.001].
Morbidity
The physicians reported on comorbidities at the first JuMBO assessment. In total, comorbidities (treatment related or not) had been reported for 41% of the patients. Those that were most frequently reported are given in Table 3 .
Additionally, physicians reported on AEs/SAEs during the follow-up in JuMBO, which included newly evolved disorders. During the observation period comprising 598 patient-years, 54 SAEs were reported, resulting in an SAE rate of 9.0 per 100 patient-years. The majority of SAEs were hospitalizations due to the rheumatic illness. Patients on ETA had an SAE rate of 5.7 per 100 patientyears. Among the SAEs were 10 infections (1.7/100 patient-years). Seven of them were observed in patients on ETA, resulting in an infection rate of 2.1/100 FIG. 2 HRQoL as measured by the SF-36 in adults with JIA recorded in JuMBO, a historical JIA group treated in the pre-biologic era and studied by Foster et al. [18] , and age-and sex-matched controls from the population [15] . www.rheumatology.oxfordjournals.org patient-years. One SAE was a death due to suicide of a 21-year-old man with enthesitis-related arthritis. At the last documentation (8 months before death), he was still on MTX, but the disease activity had been rated as mild. Comorbid conditions, especially depression, had not been reported.
Two new manifestations of IBD, two new psoriasis and four new uveitis cases were recorded. Both IBD cases and two of the four uveitis cases occurred under ETA. One patient with new-onset IBD and three patients with new-onset uveitis had enthesitis-related arthritis. De novo manifestations of systemic lupus erythematodes and neuromyelitis nervi optici were reported in one case each, of whom none had been on ETA at that time point. The rate of de novo autoimmune events was 1.7 per 100 patient-years in the whole group and 1.5 per 100 patient-years in the patients on ETA. No malignancy was observed over the observation period.
Discussion
JuMBO complements the national JIA biologics register BiKer [19] by a further follow-up of grown-up JIA patients. To our knowledge, this is the first national cohort of JIA patients treated with biologics and prospectively followed beyond adolescence. All patients included in this study had received ETA, and nearly half of them were still on this drug at the last assessment. These patients had been treated with ETA for an average of almost 5 years, with a maximum of 10 years. Such prolonged use of ETA was also observed in other JIA cohorts [20] , and this suggests that this population finds the drug tolerable and effective at controlling arthritis. Sustained benefit from ETA has also been shown in the 8-year follow-up data from a randomized controlled trial and several other JIA ETA registries [2123] .
As a matter of fact, this cohort is biased towards the severe end of the JIA spectrum, with >40% of patients having polyarticular or systemic onset of JIA. The patients included in JuMBO are those who were the first receiving ETA after licensing what was sometimes already late in the disease course.
Considering this, it is remarkable that almost half the JuMBO participants reported no functional limitations after 10 years of disease. Compared with outcome studies of patients recruited from hospital outpatients and treated in the pre-biologic era [1, 18, 24] , the JuMBO patients presented with a much better functional status.
In the majority of cases, the rheumatic disease was inactive or minimally active. Despite this, the young adults with JIA frequently reported fatigue. Fatigue is an integral part of chronic arthritis in general, and has also been a recommended outcome parameter in studies involving patients with RA [25] . By showing the frequency of fatigue in late JIA and its influence on the physical and psychosocial health, our study reveals the importance of fatigue as an outcome parameter also in JIA. Generally, the JuMBO patients reported HRQoL that was not so much different from that of a reference group from the general population [17] . In particular, the psychosocial health scores approached normative values of the general population. This is in agreement with findings by Ostile et al. [26] in a Norwegian cohort of young adults with JIA. With regard to physical health, however, the JuMBO patients judged their HRQoL lower than the reference group. But in comparison with the other adult JIA cohorts described earlier, the JuMBO patients had an impressively better HRQoL. They had SF-36 scores similar to those of patients from a population-based cohort from Rochester [27] . That is noteworthy because the Rochester cohort had a higher proportion of patients with oligoarticular-onset JIA (73 vs 18% in our study), which is known to have a better prognosis. Moreover, the JuMBO patients had much better SF-36 scores than patients from a clinic-based cohort from Newcastle with a JIA spectrum similar to that seen in JuMBO [18] . This suggests a better prognosis for the patients treated in the biologic era and adds to the evidence that severe disability and handicap have become less common than they were a decade ago [24, 28, 29] . This statement is further supported by the endoprosthesis rate of 5.9% in our study, which was lower than the rates found in adult JIA cohorts in older outcome studies, ranging from 7 to 51% [1, 18, 24, 28] . Moreover, more than twice as many JuMBO patients with a disease duration >10 years had undergone a joint operation as compared with those with a disease onset within the last 10 years. This also indicates that the improving outcome of JIA can be attributed to the dramatic treatment change that has taken place over the recent decade. DMARDs, and in particular biologic drugs, have been used earlier in the disease course and more frequently [4, 3032] . According to the German national paediatric rheumatology database, one in four patients with polyarticular JIA received a biologic drug in the year 2009 [33] .
With the increasing and prolonged use of biologics, the question about their long-term tolerance has been increasingly asked. Of course, this question cannot be answered by the first data of JuMBO, but some information in this regard has been gained. The study provided safety findings, e.g. SAE and infection rates, which are of the order, of what we know from other analyses of ETA in JIA [19, 34, 35] . One safety concern of biologic drug treatment under discussion is that the treatment could increase the risk to develop other autoimmune events. In JuMBO, new-onset autoimmune events were observed in 10 patients, 5 of them were on ETA at the time of event onset. Uveitis and IBDs were the events most frequently observed. Both of them deserve special attention because their appearance has been postulated to be related to ETA treatment [3640] . However, most events occurred in patients with enthesitis-related arthritis that has been known to be associated with increased incidence of IBD and uveitis [41, 42] . Apart from this, the number of events observed and patients followed have been too small to draw any conclusions in this respect. However, such national data collected can be used for joint risk analysis, as already done for IBD [40] .
Whether biologic drug treatment leads to a change in the comorbidity spectrum of adults with JIA has to be shown. Currently very little is known about comorbidities in these patients, and comparisons are hardly possible. JuMBO at least provides the first rates of comorbidities in adult JIA patients. Among them, uveitis, IBD and psoriasis were the most frequently reported. All can be regarded as extra-articular disease features, though a paradoxical drug response cannot be completely excluded in very few individual cases. Cardiovascular disorder, particularly hypertension, was the next most frequently reported comorbidity. According to the available data for the general population [17, 43] , it was not more common among the JuMBO patients than in the age-matched population. This is somewhat unexpected, because JIA patients are likely to be at an increased risk of early-onset cardiovascular disease. It is well documented that adults with RA are at increased risk of premature atherosclerosis and early-onset cardiovascular disease, and cardiovascular events are well-known causes of early mortality in these populations [44, 45] . Maybe the JIA patients in the JuMBO registry are still too young or disease duration and treatment are too short to have exerted a measurable influence on the cardiovascular system. Other comorbidities were rare (41%); in particular there was no malignancy, tuberculosis or any other relevant disorder with an obvious relation to treatment.
Of course, the data have to be seen in light of the study limitations. Apart from those mentioned above, the following things have to be kept in mind when interpreting the results: (i) data are presented that do not relate to all patients formerly included in BiKer, which might have biased the results. However, the patients included did not differ from those not assessed in JuMBO with regard to disease severity at the last documentation in BiKer. (ii) JuMBO is an observational cohort study with all the problems inherent to those studies. These include the lack of a comparable control group and the lack of blinding. Even though biologic-naïve JIA patients have been included as controls in JuMBO, their number was still too small to be considered as a comparator in this analysis. (iii) We cannot exclude an underreporting of AEs and SAEs. In addition, we cannot exclude the fact that we have missed some events because physician reports were available for only 75% of the patients. On the other hand, patients were asked twice a year for relevant health problems that had occurred, and the events reported were checked with physicians whenever possible.
Despite the limitations, the findings of this study are clinically important. They point to the fact that ETA treatment can prevent or reduce JIA-related damage and disability, and improve the patient's HRQoL in adulthood.
Rheumatology key messages
. The global long-term outcome of JIA has improved in the biologic era. . Fatigue is an important outcome parameter and influences global health in JIA. . ETA offers an acceptable safety profile for patients with JIA.
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